l-dopa/benserazid-50/12,5 mg tabletten
ratiopharm gmbh - levodopa, benserazidhydrochlorid - tablette - levodopa 50.mg; benserazidhydrochlorid 14.25mg
l-dopa/benserazid-200/50 mg tabletten
ratiopharm gmbh - levodopa, benserazidhydrochlorid - tablette - levodopa 200.mg; benserazidhydrochlorid 57.mg
l-dopa/benserazid-100/25 mg tabletten
ratiopharm gmbh - levodopa, benserazidhydrochlorid - tablette - levodopa 100.mg; benserazidhydrochlorid 28.5mg
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - aminosäuremetabolismus, angeborene fehler - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.
numient
amneal pharma europe ltd - levodopa, carbidopa - parkinson krankheit - anti-parkinson-medikamente - symptomatische behandlung von erwachsenen patienten mit parkinson-krankheit.
trimbow
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarat dihydrat, glycopyrronium bromide - lungenerkrankung, chronisch obstruktiv - medikamente für obstruktive atemwegserkrankungen, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
riltrava aerosphere
astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - lungenerkrankung, chronisch obstruktiv - medikamente für obstruktive atemwegserkrankungen, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.
l-dopa-ratiopharm 250 kapsel
ratiopharm gmbh - levodopa - kapsel - levodopa 250.mg
l-dopa-ratiopharm 500 kapsel
ratiopharm gmbh - levodopa - kapsel - levodopa 500.mg
axura
merz pharmaceuticals gmbh - memantinhydrochlorid - alzheimer - andere anti-demenz-medikamente - behandlung von patienten mit mittelschwerer bis schwerer alzheimer-krankheit.